Vivos Therapeutics, Inc.
VVOS
$2.63
-$0.08-2.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.03M | 14.58M | 14.02M | 13.36M | 13.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.03M | 14.58M | 14.02M | 13.36M | 13.80M |
| Cost of Revenue | 6.01M | 5.57M | 5.60M | 5.49M | 5.53M |
| Gross Profit | 9.02M | 9.01M | 8.42M | 7.87M | 8.27M |
| SG&A Expenses | 19.61M | 20.92M | 21.33M | 23.35M | 24.94M |
| Depreciation & Amortization | 581.00K | 586.00K | 590.00K | 593.00K | 622.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.20M | 27.08M | 27.52M | 29.44M | 31.10M |
| Operating Income | -11.17M | -12.50M | -13.49M | -16.08M | -17.30M |
| Income Before Tax | -11.14M | -12.57M | -12.05M | -15.64M | -13.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.14 | -12.57 | -12.05 | -15.64 | -13.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.14M | -12.57M | -12.05M | -15.64M | -13.58M |
| EBIT | -11.17M | -12.50M | -13.49M | -16.08M | -17.30M |
| EBITDA | -10.59M | -11.91M | -12.91M | -15.48M | -16.67M |
| EPS Basic | -3.23 | -5.84 | -6.98 | -11.00 | -11.08 |
| Normalized Basic EPS | -2.02 | -3.65 | -4.36 | -6.87 | -6.93 |
| EPS Diluted | -3.23 | -5.84 | -6.98 | -11.00 | -11.08 |
| Normalized Diluted EPS | -2.02 | -3.65 | -4.36 | -6.87 | -6.93 |
| Average Basic Shares Outstanding | 17.05M | 11.24M | 8.15M | 6.12M | 4.81M |
| Average Diluted Shares Outstanding | 17.05M | 11.24M | 8.15M | 6.12M | 4.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |